Product overview

Name GSK J4
Alternative names GSK-J4; GSKJ4
Purity >99%
Description JMJD3 / UTX Histone demethylase inhibitor
Write Your Own Review
You're reviewing:GSK J4
Rate this item:

Biological Data

Biological description JMJD3 and UTX histone demethylase inhibitor,GSK J1 prodrug. Cell permeable. Reduces macrophage proinflammatory cytokine production. Improves survival in Cardio-facio-cutaneous (CFC) syndrome in mice and inhibits growth of T-cell acute lymphoblastic leukaemia cancer cells.

Solubility & Handling

Storage instructions Room temperature
Solubility overview Soluble in DMSO (100mM) or ethanol (100mM)
Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

Calculators

Molarity

=
x
x
More Info

Dilution

x
=
x
More Info

Chemical Data

Purity >99%
Chemical name N-[2-(2-Pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-β-alanin e ethyl ester
Molecular Weight 417.5
Chemical structure GSK J4  [1373423-53-0] Chemical Structure
Molecular Formula C24H27N5O2
CAS Number 1373423-53-0
PubChem identifier 71729975
SMILES O=C(CCNC1=NC(C2=CC=CC=N2)=NC(N3CCC(C=CC=C4)=C4CC3)=C1)OCC
InChiKey WBKCKEHGXNWYMO-UHFFFAOYSA-N

References for GSK J4

References are publications that support the biological activity of the product
  • New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome.

    Inoue S et al (2014) Hum Mol Genet 23(24) : 6553-66.
  • Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia.

    Ntziachristos P et al (2014) Nature 514(7523) : 513-7.
  • A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.

    Kruidenier L et al (2012) Nature 488(7411) : 404-8.

3 Item(s)